Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: A pharmacokinetic and pharmacodynamic study

Diabetes Care

Volumn 33, Issue 12, 2010, Pages 2502-2507

  Gagnon Auger, Maude ^a   Du Souich, Patrick ^b   Baillargeon, Jean Patrice ^a,c   Martin, Elisabeth ^a   Brassard, Pascal ^c   Ménard, Julie ^c   Ardilouze, Jean Luc ^a,c  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Centre Hospitalier Universitaire de Sherbrooke   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LISPRO; XENON 133;

ADIPOSE TISSUE BLOOD FLOW; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; HYPOGLYCEMIA; INFUSION RATE; INSULIN TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 79951687942     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1126     Document Type: Article

References (25)

1. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-183 (Pubitemid 40096614)
2. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003;26:2027-2031 (Pubitemid 41184246)
3. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-1506 (Pubitemid 29418246)
4. ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996;19:1437-1440
5. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005;113:435-443 (Pubitemid 41360749)
6. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and non obese NIDDM patients. Diabetes Care 1995;18:986-991
7. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-79
8. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-767 (Pubitemid 32888861)
9. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients: influence of species, physicochemical properties of insulin and physiological factors. Dan Med Bull 1991;38:337-346
10. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-380
11. Hildebrandt P, Birch K, Sestoft L, Volund A. Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins. Acta Med Scand 1984;215:69-73 (Pubitemid 14216503)
12. Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in diabetic patients. Acta Physiol Scand Suppl 1991;603:41-45
13. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 1992;15:1484-1493
14. Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MT, Heidendal GA, Saris WH. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995;44:183-187
15. Dimitriadis G, Lambadiari V, Mitrou P, Maratou E, Boutati E, Panagiotakos DB, Economopoulos T, Raptis SA. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 2007;30:3128-3130 (Pubitemid 350255263)
16. Ardilouze JL, Fielding BA, Currie JM, Frayn KN, Karpe F. Nitric oxide and beta adrenergic stimulation are major regulators of pre- and postprandial subcutaneous adipose tissue blood flow in humans. Circulation 2004;109:47-52 (Pubitemid 38056020)
17. Yki-Järvinen H, Koivisto VA, Karonen SL. Influence of body composition on insulin clearance. Clin Physiol 1985;5:45-52 (Pubitemid 15127754)
18. Rave KM, Nosek L, de la Pena A, Seger M, Ernest II CS, Heinemann L, Batycky RP, Muchmore DB. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-2405
19. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44:305-308 (Pubitemid 32234455)
20. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758 (Pubitemid 30339990)
21. Barnett AH. How well do rapid-acting insulins work in obese individuals? Diabetes Obes Metab 2006;8:388-395
22. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-397
23. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-1344 (Pubitemid 40973416)
24. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Oncedaily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084 (Pubitemid 351436611)
25. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747